HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

epoxyfarnesyl diazoacetate

Also Known As:

EFDA

Networked: 6 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Sarafianos, Stefan G: 4 articles (07/2015 - 03/2012)
2.	Parniak, Michael A: 3 articles (07/2015 - 09/2012)
3.	Mitsuya, Hiroaki: 3 articles (04/2014 - 03/2012)
4.	Galkina, Sofiya A: 2 articles (01/2019 - 07/2015)
5.	Joshi, Pheroze: 2 articles (01/2019 - 07/2015)
6.	Kosikova, Galina: 2 articles (01/2019 - 07/2015)
7.	Moreno, Mary E: 2 articles (01/2019 - 07/2015)
8.	Rivera, Jose M: 2 articles (01/2019 - 07/2015)
9.	Stoddart, Cheryl A: 2 articles (01/2019 - 07/2015)
10.	Murphey-Corb, Michael: 2 articles (07/2015 - 09/2012)

Related Diseases

1.	HIV Infections (HIV Infection) 06/05/2014 - "Furthermore, in vivo efficacy and safety evaluations have shown EFdA to be a promising therapeutic candidate for use in the treatment of HIV infection. " 03/01/2012 - "The potent antiretroviral 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) is a promising experimental agent for treating HIV infection. " 07/01/2015 - "Daily oral administration of EFdA at low dosage levels (1 to 10 mg/kg/day) was highly effective in protecting humanized mice from HIV infection, and 10 mg/kg/day oral EFdA completely suppressed HIV RNA to undetectable levels within 2 weeks of treatment."
2.	Infections 01/01/2019 - "Using a combination of RNAscope in situ hybridization (ISH) and immunohistochemistry (IHC), we quantitatively investigated the distribution of HIV in the lymphoid tissues of humanized mice during active infection, EFdA suppression, and after drug cessation. " 07/01/2015 - "Rhesus PBMCs isolated 24 h following a single oral dose of 5 mg/kg EFdA were refractory to SIV infection due to sufficiently high intracellular EFdA-triphosphate levels. " 04/01/2014 - "EFdA, a reverse transcriptase inhibitor, potently blocks HIV-1 ex vivo infection of Langerhans cells within epithelium." 09/01/2012 - "EFdA was 3 orders of magnitude better than tenofovir (TFV), zidovudine (AZT), and emtricitabine (FTC) in blocking replication of SIV in monkey peripheral blood mononuclear cells (PBMCs) in vitro, and in a preliminary study using two SIV-infected macaques with advanced AIDS, it was highly effective at treating SIV infection and AIDS symptoms in vivo. "
3.	Acquired Immunodeficiency Syndrome (AIDS) 09/01/2012 - "EFdA was 3 orders of magnitude better than tenofovir (TFV), zidovudine (AZT), and emtricitabine (FTC) in blocking replication of SIV in monkey peripheral blood mononuclear cells (PBMCs) in vitro, and in a preliminary study using two SIV-infected macaques with advanced AIDS, it was highly effective at treating SIV infection and AIDS symptoms in vivo. "
4.	Body Weight (Weight, Body) 07/01/2015 - "EFdA was readily absorbed after oral dosing (5 mg/kg of body weight) in both mice and the rhesus macaque, with micromolar levels of the maximum concentration of drug in serum (Cmax) attained at 30 min and 90 min, respectively. " 09/01/2012 - "Both animals had 3- to 4-log decreases in plasma virus burden within 1 week of EFdA therapy (0.4 mg/kg of body weight, delivered subcutaneously twice a day) that eventually became undetectable. "
5.	Viremia 07/01/2015 - "Oral administration of the nucleoside EFdA (4'-ethynyl-2-fluoro-2'-deoxyadenosine) provides rapid suppression of HIV viremia in humanized mice and favorable pharmacokinetic properties in mice and the rhesus macaque."

Related Drugs and Biologics

1.	RNA (Ribonucleic Acid)
2.	Zidovudine (Retrovir)
3.	Tenofovir (Viread)
4.	Emtricitabine (Emtriva)
5.	Racivir
6.	Reverse Transcriptase Inhibitors
7.	Nucleosides
8.	islatravir
9.	triphosphoric acid (triphosphate)

Related Therapies and Procedures

1.	Oral Administration
2.	Therapeutics